{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:11:29Z","timestamp":1793635889489,"version":"4.5.1"},"reference-count":29,"publisher":"Centers for Disease Control MMWR Office","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Recomm. Rep."],"DOI":"10.15585\/mmwr.rr7302a1","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T13:45:54Z","timestamp":1717508754000},"page":"1-8","source":"Crossref","is-referenced-by-count":261,"title":["CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024"],"prefix":"10.15585","volume":"73","author":[{"given":"Laura H.","family":"Bachmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindley A.","family":"Barbee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Reno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Workowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mermin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R1","unstructured":"CDC. Sexually transmitted infections surveillance 2022. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/std\/statistics\/2022\/default.htm"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R2","unstructured":"US Department of Health and Human Services. Sexually transmitted infections national strategic plan for the United States: 2021\u20132025. Washington DC: US Department of Health and Human Services; 2020."},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R3","doi-asserted-by":"crossref","unstructured":"Nadelman RB, Nowakowski J, Fish D, ; Tick Bite Study Group. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001;345:79\u201384 10.1056\/NEJM200107123450201.11450675","DOI":"10.1056\/NEJM200107123450201"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R4","first-page":"553","article-title":"Doxycycline in the management of sexually transmitted infections.","volume":"73","author":"Peyriere","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R5","doi-asserted-by":"crossref","unstructured":"Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf 2008;7:571\u20137 10.1517\/14740338.7.5.571.18759709","DOI":"10.1517\/14740338.7.5.571"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R6","doi-asserted-by":"crossref","unstructured":"Workowski KA, Bachmann LH, Chan PA,  Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1\u2013187 10.15585\/mmwr.rr7004a1.34292926","DOI":"10.15585\/mmwr.rr7004a1"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R7","unstructured":"CDC. Sexually transmitted disease surveillance 2022: Gonococcal Isolate Surveillance Project National Profile. Atlanta, GA: U. Department of Health and Human Services, CDC; 2024."},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R8","doi-asserted-by":"crossref","unstructured":"Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis 2015;42:98\u2013103 10.1097\/OLQ.0000000000000216.25585069","DOI":"10.1097\/OLQ.0000000000000216"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R9","doi-asserted-by":"crossref","unstructured":"Werner RN, Schmidt AJ, Potthoff A,  Society (DSTIG). Position statement of the German STI Society on the prophylactic use of doxycycline to prevent STIs (Doxy-PEP, Doxy-PrEP). J Dtsch Dermatol Ges 2024;22:466\u201378 10.1111\/ddg.15282.38123738","DOI":"10.1111\/ddg.15282"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R10","doi-asserted-by":"crossref","unstructured":"Cornelisse VJ, Riley B, Medland NA. Australian consensus statement on doxycycline post-exposure prophylaxis (doxy-PEP) for the prevention of syphilis, chlamydia and gonorrhoea among gay, bisexual and other men who have sex with men. Med J Aust 2024;220:381\u20136 10.5694\/mja2.52258.38479437","DOI":"10.5694\/mja2.52258"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R11","doi-asserted-by":"crossref","unstructured":"M\u00e5rdh O, Plachouras D. Using doxycycline for prophylaxis of bacterial sexually transmitted infections: considerations for the European Union and European Economic Area. Euro Surveill 2023;28:2300621 10.2807\/1560-7917.ES.2023.28.46.2300621.37971658","DOI":"10.2807\/1560-7917.ES.2023.28.46.2300621"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R12","unstructured":"US Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents: guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC: US Department of Health and Human Services; 2022. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R13","unstructured":"Molina JM, Charreau I, Chidiac C, ; ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018;18:308\u201317 10.1016\/S1473-3099(17)30725-9.29229440"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R14","doi-asserted-by":"crossref","unstructured":"Luetkemeyer AF, Donnell D, Dombrowski JC,  Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med 2023;388:1296\u2013306 10.1056\/NEJMoa2211934.37018493","DOI":"10.1056\/NEJMoa2211934"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R15","unstructured":"Molina JM, Bercos B, Assoumou L, , editors. ANRS 174 DOXYVAC: an open-label randomized 253 trial to prevent STIs in MSM on PrEP [Abstract 119]. Abstracts from Conference on Retroviruses and Opportunistic Infections; February 19\u201322, 2023; Seattle, WA. San Francisco, CA: International Antiviral Society\u2014USA2023:21."},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R16","doi-asserted-by":"crossref","unstructured":"Stewart J, Oware K, Donnell D,  dPEP Kenya Study Team. dPEP Kenya Study Team. Doxycycline prophylaxis to prevent sexually transmitted infections in women. N Engl J Med 2023;389:2331\u201340 10.1056\/NEJMoa2304007.38118022","DOI":"10.1056\/NEJMoa2304007"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R17","unstructured":"Stewart JOK, Donnell D, Violette L,  Self-reported adherence to event-driven doxycycline postexposure prophylaxis for sexually transmitted infection prevention among cisgender women. STI and HIV World Congress; Chicago, IL: 2023 July 24, 2023."},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R18","doi-asserted-by":"crossref","unstructured":"Chan PA, Le Brazidec DL, Becasen JS,  Safety of longer-term doxycycline use: a systematic review and meta-analysis with implications for bacterial sexually transmitted infection chemoprophylaxis. Sex Transm Dis 2023;50:701\u201312 10.1097\/OLQ.0000000000001865.37732844","DOI":"10.1097\/OLQ.0000000000001865"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R19","unstructured":"Luetkemeyer ADD, Dombrowski J, Cohen S,  DoxyPEP and antimicrobial resistance in N. gonorrhoeae, commensal Neisseria and S. aureus. Conference on Retroviruses and Opportunistic Infections; 2023; Seattle, WA."},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R20","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoint tables for intepretation of MICs and zone diameter (Version 13.1). Kronoberg, Sweden: European Committee on the Antimicrobial Susceptibility Testing; 2023. https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R21","doi-asserted-by":"crossref","unstructured":"Morse SA, Johnson SR, Biddle JW, Roberts MC. High-level tetracycline resistance in Neisseria gonorrhoeae is result of acquisition of streptococcal tetM determinant. Antimicrob Agents Chemother 1986;30:664\u201370 10.1128\/AAC.30.5.664.3099640","DOI":"10.1128\/AAC.30.5.664"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R22","doi-asserted-by":"crossref","unstructured":"Moon SH, Roh HS, Kim YH, Kim JE, Ko JY, Ro YS. Antibiotic resistance of microbial strains isolated from Korean acne patients. J Dermatol 2012;39:833\u20137 10.1111\/j.1346-8138.2012.01626.x.22779738","DOI":"10.1111\/j.1346-8138.2012.01626.x"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R23","doi-asserted-by":"crossref","unstructured":"Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg 1990;43:608\u201313 10.4269\/ajtmh.1990.43.608.2267964","DOI":"10.4269\/ajtmh.1990.43.608"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R24","doi-asserted-by":"crossref","unstructured":"Lesens O, Haus-Cheymol R, Dubrous P,  Working Group on Cutaneous Infections in the Army. Methicillin-susceptible, doxycycline-resistant Staphylococcus aureus, C\u00f4te d\u2019Ivoire. Emerg Infect Dis 2007;13:488\u201390 10.3201\/eid1303.060729.17552109","DOI":"10.3201\/eid1303.060729"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R25","doi-asserted-by":"crossref","unstructured":"Traeger MW, Cornelisse VJ, Asselin J,  PrEPX Study Team. PrEPX Study Team. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 2019;321:1380\u201390 10.1001\/jama.2019.2947.30964528","DOI":"10.1001\/jama.2019.2947"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R26","doi-asserted-by":"crossref","unstructured":"Wilson DP, Prestage GP, Gray RT,  Chemoprophylaxis is likely to be acceptable and could mitigate syphilis epidemics among populations of gay men. Sex Transm Dis 2011;38:573\u20139 10.1097\/OLQ.0b013e31820e64fd.21343845","DOI":"10.1097\/OLQ.0b013e31820e64fd"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R27","doi-asserted-by":"crossref","unstructured":"Grant JS, Stafylis C, Celum C,  Doxycycline prophylaxis for bacterial sexually transmitted infections. Clin Infect Dis 2020;70:1247\u201353 10.1093\/cid\/ciz866.31504345","DOI":"10.1093\/cid\/ciz866"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R28","doi-asserted-by":"crossref","unstructured":"Zeggagh J, Bauer R, Delaugerre C, ; Ipergay Study Group. Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis. AIDS 2022;36:1129\u201334 10.1097\/QAD.0000000000003187.35142708","DOI":"10.1097\/QAD.0000000000003187"},{"key":"key-10.15585\/mmwr.rr7302a1-202405310840-R29","doi-asserted-by":"crossref","unstructured":"Traeger MW, Mayer KH, Krakower DS, Gitin S, Jenness SM, Marcus JL. Potential impact of doxycycline post-exposure prophylaxis prescribing strategies on incidence of bacterial sexually transmitted infections. Clin Infect Dis 2023:ciad488. 10.1093\/cid\/ciad48837595139","DOI":"10.1093\/cid\/ciad488"}],"container-title":["MMWR. Recommendations and Reports"],"original-title":[],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T13:46:13Z","timestamp":1717508773000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/73\/rr\/rr7302a1.htm?s_cid=rr7302a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6,6]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.rr7302a1","relation":{},"ISSN":["1057-5987","1545-8601"],"issn-type":[{"value":"1057-5987","type":"print"},{"value":"1545-8601","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,6]]},"published":{"date-parts":[[2024,6,6]]}}}